Compare Quest Diagnostics Inc (DGX) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Manulife Financial Corporation — how do they compare? Quest Diagnostics Inc trades at $230.8 (market cap $25.48B), while Manulife Financial Corporation trades at $42.32 (market cap $69.48B). The key difference: Manulife Financial Corporation is far larger — about 2.7× Quest Diagnostics Inc's market cap, and Manulife Financial Corporation pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Manulife Financial Corporation for 119 Days on average.
| DGX | MFC | |
|---|---|---|
Market Cap | $25.48B | $69.48B |
Volume | 941,866 | 1,347,508 |
Sector | Health | Financials |
52-Week High | $247.45 | $44.77 |
52-Week Low | $173.49 | $31.64 |
Typical Hold Time | 56 Days | 119 Days |
Enterprise Value | $31.23B | $64.75B |
Dividend Yield | 1.49% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
MFC trades at $42.33, up 1.58% today, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $53.01B in 2025 to projected $57.5B in 2026, with net income margins around 11%. Recent institutional investments from Bank of America and executive appointments signal confidence. However, the stock trades above the $34.24 consensus price target, suggesting limited near-term upside.
The outlook remains mixed with solid fundamentals but valuation concerns. Investment opportunity lies in continued Asia growth and insurance sales momentum, while risks include premium valuation and potential earnings volatility. Analyst consensus leans bullish with 57% buy ratings, but technical indicators warn of near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
